ARVN - Wells Fargo upgrades Arvinas to overweight ahead of Phase 3 data readout
2023-12-19 13:36:10 ET
More on Arvinas
- Arvinas: Positive Breast Cancer Data Leads To Other Developments
- Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity
- Jefferies upgrades Arvinas to buy in wake of positive ARV-471 data
- Arvinas stock jumps 30% amid positive data for breast cancer drug
- Seeking Alpha’s Quant Rating on Arvinas
For further details see:
Wells Fargo upgrades Arvinas to overweight ahead of Phase 3 data readout